Sydney’s Tetratherix, a start-up founded by USyd researcher Ali Fathi to commercialise a new biomaterial for regenerative medicine, is mulling life on the ASX boards.
Tetratherix claims its biomaterial (pictured) can help tissue regeneration without major side effects.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
